Head-To-Head Analysis: Affymetrix (AFFX) & Iovance Biotherapeutics (IOVA)
Affymetrix (NASDAQ: AFFX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.
This table compares Affymetrix and Iovance Biotherapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
75.9% of Iovance Biotherapeutics shares are owned by institutional investors. 13.2% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Affymetrix and Iovance Biotherapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Iovance Biotherapeutics||N/A||N/A||-$52.89 million||($1.30)||-6.31|
Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Affymetrix, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations for Affymetrix and Iovance Biotherapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Iovance Biotherapeutics has a consensus target price of $15.31, indicating a potential upside of 86.74%. Given Iovance Biotherapeutics’ higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Affymetrix.
Affymetrix Company Profile
Affymetrix, Inc. (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry. The eBioscience segment primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. It maintains sales and distribution operations across the United States, Europe, Latin America and Asia.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Receive News & Ratings for Affymetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymetrix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.